NY-MEDIDATA
Medidata , a Dassault Systèmes company, announced 10 highly innovative organizations have joined its groundbreaking Sensor Cloud Network . AliveCor, Aural Analytics, Biobeat, Blue Spark Technologies, Glooko, Indie Health, University of Arizona, Carnegie Mellon University, University of Rochester, and University of Vermont are now part of the first cross-sector collaboration focused on solving the challenges related to sensor integrations, standardization of sensor data, and the development of novel digital biomarkers and algorithms. These will help to create new digital endpoints that could translate into more effective treatments and better healthcare for patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005239/en/
The Sensor Cloud Network, which includes contract research organizations (CROs), device manufacturers, drug and vaccine developers, analytics companies, and academic institutions, creates opportunities for data scientists to refine, test, and deliver physiological algorithms with clinical meaning at scale. Examples include refined motion parameters like gait, cardiovascular metrics, metabolic insights, and clinical-grade speech analytics.
“As the use of sensors in clinical trials is predicted to reach 50% by 20251 , we are focused on making Medidata Sensor Cloud the industry standard for collecting and analyzing medical-grade sensor data,” said Ben Schlatka, vice president, Digital Biomarker Solutions at Medidata. “We are excited to work with a diverse group of partners to help shape the future of patient data collection and analysis, and make Sensor Cloud the platform of choice for developing new digital biomarkers across a wide variety of therapeutic areas.”
Comments from the newest Sensor Cloud Network partners:
“AliveCor is pleased to join the Medidata Sensor Cloud Network to help facilitate and expand access to clinical trials for a range of serious conditions. Medidata and AliveCor are democratizing clinical research by providing a reliable way to remotely capture and share important heart health data,” said Aman Bhatti, M.D., senior vice president, Global Biopharma, AliveCor, a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology.
"Aural Analytics is thrilled to partner with an industry leader like Medidata. The inclusion of our technology in Medidata’s innovative platform will greatly enhance its capacity for speech collection and analysis," said Judy Smythe, CEO of Aural Analytics, the industry’s leading neuroscience company harnessing the clinical utility of speech across age ranges and around the world.
“We eagerly look forward to collaborating with Medidata and its partners, as we jointly support and advance the decentralized clinical trial (DCT) process with AI-powered remote patient monitoring technology to better aggregate patient data,” said Arik Ben Ishay, CEO of Biobeat , a medtech company with unique health-AI capabilities in the patient monitoring space.
“Blue Spark is excited to become one of the first members of Medidata Sensor Cloud Network. The integration of our TempTraq wearable, wireless continuous temperature monitoring platform gives researchers access to real-time continuous human body temperature data, fed right into the Sensor Cloud Network. TempTraq has been clinically shown to detect fevers up to 18 hours earlier than the standard of care,” said John Gannon, president and CEO of Blue Spark Technologies, Inc., an innovator in wearable, medical device solutions.
“We are very pleased to partner with Medidata’s Sensor Cloud team in making it easier for Life Science organizations to execute global clinical trials, using Glooko’s Connected Research platform. This will benefit researchers in collecting digital endpoints while providing patients with a better trial experience, which will ultimately result in more efficient development of new and novel therapeutics for all disease states,” said Komathi Stem, Chief Operating Officer of Glooko , a digital health company that uses AI/ML algorithms to deliver precision engagement, transform care, and accelerate clinical research.
"We are thrilled to announce this unique partnership with the Medidata Sensor Cloud Network as both of our companies believe that moving clinical research to the home with decentralized data collection will improve the quality of the industry, translating to overall improvements in treatments," said Clint McClellan, CEO, Indie Health , which makes decentralized clinical trials and remote patient monitoring easy, affordable, scalable, and reliable.
“We are leveraging the tools and technology available in the Medidata Sensor Cloud Network to advance and accelerate our work in the development of fall risk detection algorithms in the Multiple Sclerosis population, a disease that affects 2.3M patients worldwide, 50% of whom will experience a fall that negatively impacts their quality of life,” said Dr. Ryan McGinnis, Head of the MSense group at the University of Vermont . “The Sensor Cloud Network is allowing us to explore the combination of patient reported outcomes and medical-grade wearables data in remote settings at scale to better understand this problem and to develop a digital intervention.”
To learn more about the Sensor Cloud Network, please visit here .
Medidata is a wholly-owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.
- Y. Jansen and G. Thornton, “Wearables & Big Data In Clinical Trials — Where Do We Stand?,” Clinical Leader, February 2020. https://www.clinicalleader.com/doc/wearables-big-data-in-clinical-trials-where-do-we-stand-0001 .
About Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 2,000+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata .
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com .
3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005239/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dubai Brings Together Sport Stars and Legends, Leaders and Decision-Makers on the Largest Global Platform to Shape the Future of Sports: the World Sports Summit18.12.2025 14:40:00 CET | Press release
Under the directives of His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum and the supervision of the Dubai Sports Council- The Summit, under the theme ‘Uniting the World Through Sports’, aligns with the objectives of Dubai Sports Sector Strategic Plan 2033- A comprehensive programme will address the future of sports, development of the sector and more The Dubai Sports Council has announced the launch of the World Sports Summit (WSS), which will take place under the directives of His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister, Minister of Defence and Chairman of the Executive Council of Dubai. The event is set to be held from December 29-30, 2025 at Madinat Jumeirah in Dubai, under the theme ‘Uniting the World Through Sports’. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218607571/en/ Dubai Brings Together Sport Stars and Legends, Leaders and Decisi
Regula Wins High Customer Marks and Strong Momentum in G2’s Winter 2026 Grid Reports for Identity Verification18.12.2025 14:11:00 CET | Press release
Regula, a global developer of identity verification solutions, has been recognized by customers on G2’s review platform as one of the fastest-rising and most trusted vendors in the identity verification market. Regula is named as a Leader in three G2 Winter 2026 Grid® Reports for Identity Verification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218134153/en/ Regula is recognized as a Leader in G2’s Winter 2026 Grid Reports for Identity Verification, reflecting strong customer satisfaction and enterprise-grade IDV capabilities. This season, Regula earned a Leader placement in G2’s Overall Grid® for Identity Verification Software, reflecting strong customer satisfaction and a growing presence in the market. The company was also named a Leader in the Momentum Grid® Report for Identity Verification, highlighting accelerating demand for Regula’s solutions and increasingly positive feedback from users. In addition, Regula a
Aptiv and Vecna Robotics to Develop Next Generation Autonomous Mobile Robots18.12.2025 14:00:00 CET | Press release
Collaboration to Deliver Safer, Smarter, and Cost-Effective Automation for Warehouses and Factories Aptiv PLC (NYSE: APTV), a global industrial technology leader, and Vecna Robotics, a pioneer in AI-driven autonomous material handling solutions, today announced a strategic collaboration to co-develop next-generation Autonomous Mobile Robot (AMR) solutions designed to deliver cost-efficient automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218958100/en/ Aptiv’s advanced perception portfolio and machine learning technologies will be integrated into Vecna Robotics’ platform. This partnership combines Aptiv’s industry-leading portfolio, with Vecna Robotics’ advanced autonomy and orchestration platform to provide safer, more efficient, and scalable material handling systems. “Automation is transforming the way goods move through warehouses and factories, with devices that sense, think and act in real time,” said Javed
Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions18.12.2025 14:00:00 CET | Press release
Addressing major unmet needs in mental health with pharmacology rooted in emerging and clinically validated neuropsychiatric biologyLead program ST-905, a potent M1/M4 muscarinic agonist, currently in Phase 1 clinical developmentSecond program ST-901, a novel NMDA antagonist, currently in IND-enabling studies and expected to enter Phase 1 development next yearSeries A co-led by Dexcel Pharma and Third Rock Ventures with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet Syremis Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health, today announced its launch with a $165 million financing. The Series A, co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet will support the advancement of Syremis’ pipeline through clinical proof of concept. Schizophrenia and other psychotic disorder
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
